Merck Seen As Late-Riser In HCV Combo Race, As Some Competitors Fade
Executive Summary
Gilead is still viewed as clear leader to get first all-oral combo to the U.S. market for chronic hepatitis C. Heading into this year’s AASLD conference, AbbVie and Bristol, along with Merck, are also working to get combos to market to take at least a piece of the mega-blockbuster market for next-generation HCV therapies.